Fluorous bispidine: a bifunctional reagent for copper-catalyzed oxidation and knoevenagel condensation reactions in water
作者:Wei Jie Ang、Yong Sheng Chng、Yulin Lam
DOI:10.1039/c5ra17093a
日期:——
Fluorous bispidine-type ligands have been developed to demonstrate its bifunctional property as a ligand and base in copper-catalyzed aerobic oxidation, the Knoevenagel condensation and tandem oxidation/condensation in water under mild conditions.
t-butoxide catalyses the title reaction between aromatic aldehydes and malononitrile or alkyl cyanoacetates. At ambient temperatures, this procedure specifically gives high yields of E olefinic Knoevenagel products.
[EN] 4H-PYRAN COMPOUNDS AS INSULIN-REGULATED AMINOPEPTIDASE (IRAP) INHIBITORS<br/>[FR] COMPOSÉS 4H-PYRANE UTILISÉS COMME INHIBITEURS DE L'AMINOPEPTIDASE RÉGULÉE PAR L'INSULINE (IRAP)
申请人:UNIV MONASH
公开号:WO2016179645A1
公开(公告)日:2016-11-17
The present disclosure relates to 4H-pyran compounds of formula (I) and their use in therapy, to compositions and agents comprising said compounds, to methods of treatment using said compounds, and their use in the manufacture of medicaments. The disclosure further relates to said compounds and compositions thereof as inhibitors of IRAP and their use in the treatment or prevention of Alzheimer's disease and the treatment and prevention of memory and cognitive disorders.
Electrochemical approach for synthesis of 3-substituted indole derivatives
作者:Vinay K. Singh、Rahul Dubey、Abhishek Upadhyay、Laxmi Kant Sharma、Rana Krishna Pal Singh
DOI:10.1016/j.tetlet.2017.09.003
日期:2017.11
An efficient and economical method was developed for synthesis of 3-substituted indole by using electrochemically induced condensation of various aldehyde, indole and malononitrile.
通过利用电化学诱导的各种醛,吲哚和丙二腈的缩合反应,开发了一种高效经济的方法来合成3-取代的吲哚。
[EN] FIBROTIC TREATMENT<br/>[FR] TRAITEMENT DE LA FIBROSE
申请人:UNIV MONASH
公开号:WO2017015720A1
公开(公告)日:2017-02-02
The present invention relates to a method for the treatment of fibrosis, in particular cardiac fibrosis, comprising the administration of an inhibitor of insulin-regulated aminopeptidase (IRAP). Preferable the IRAP inhibitor is chosen from the group including HFI- 419, HA-08, AL-40, HFI-437, Val-Tyr-Ile-His-Pro-Phe (otherwise known as angiotensin IV or ANG IV), c[Cys-Tyr-Cys]-His-Pro- Phe, and c[Hcy-Tyr-Hcy]-His-Pro-Phe.